Echo Therapeutics, Inc. (ECTE.OB) Announces Positive Results of a Clinical Study for Patients with Type 1 and Type 2 Diabetes
Echo Therapeutics, Inc., a company developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in acute and critical care, recently announced positive results of a clinical study of its Symphony tCGM System in patients with Type 1 and Type 2 diabetes. The purpose of the study was to test the performance of the company’s new, improved one-piece, cost-effective and easy-to-use biosensor. Echo Therapeutics’ non-invasive Symphony tCGM System consists of its wireless transmission and transdermal biosensor technologies and is designed to provide diabetic patients with an affordable and easy-to-use,…